Does the media favor SPRY or ETON?

In the previous week, ARS Pharmaceuticals and ARS Pharmaceuticals both had 6 articles in the media. Eton Pharmaceuticals' average media sentiment score of 0.45 beat ARS Pharmaceuticals' score of 0.16 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eton Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer GHRS or SPRY?

In the previous week, ARS Pharmaceuticals had 2 more articles in the media than GH Research. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 4 mentions for GH Research. GH Research's average media sentiment score of 0.45 beat ARS Pharmaceuticals' score of 0.16 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RAPP or SPRY?

In the previous week, Rapport Therapeutics had 5 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 11 mentions for Rapport Therapeutics and 6 mentions for ARS Pharmaceuticals. Rapport Therapeutics' average media sentiment score of 0.54 beat ARS Pharmaceuticals' score of 0.16 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to OCUL or SPRY?

In the previous week, Ocular Therapeutix had 6 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 12 mentions for Ocular Therapeutix and 6 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.16 beat Ocular Therapeutix's score of 0.11 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PAHC or SPRY?

In the previous week, ARS Pharmaceuticals had 3 more articles in the media than Phibro Animal Health. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 3 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.50 beat ARS Pharmaceuticals' score of 0.16 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ARS Pharmaceuticals (SPRY) Competitors

$4.23 -0.33 (-7.24%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.29 +0.06 (+1.39%)

As of 10/9/2026 07:30 PM Eastern

Compare

SPRY vs. ETON, GHRS, RAPP, OCUL, and PAHC

Should you buy ARS Pharmaceuticals stock or one of its competitors? ARS Pharmaceuticals's main competitors and comparable companies include Eton Pharmaceuticals (ETON), GH Research (GHRS), Rapport Therapeutics (RAPP), Ocular Therapeutix (OCUL), and Phibro Animal Health (PAHC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ARS Pharmaceuticals compare to Eton Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

In the previous week, ARS Pharmaceuticals and ARS Pharmaceuticals both had 6 articles in the media. Eton Pharmaceuticals' average media sentiment score of 0.45 beat ARS Pharmaceuticals' score of 0.16 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ARS Pharmaceuticals has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Eton Pharmaceuticals has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$116.93M	3.60	-$171.30M	-$2.18	N/A
Eton Pharmaceuticals	$79.95M	19.74	-$4.60M	$0.38	145.29

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ARS Pharmaceuticals presently has a consensus target price of $25.00, suggesting a potential upside of 491.02%. Eton Pharmaceuticals has a consensus target price of $67.50, suggesting a potential upside of 22.26%. Given ARS Pharmaceuticals' higher probable upside, equities research analysts plainly believe ARS Pharmaceuticals is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Eton Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Eton Pharmaceuticals has a net margin of 12.02% compared to ARS Pharmaceuticals' net margin of -184.24%. Eton Pharmaceuticals' return on equity of 40.13% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%
Eton Pharmaceuticals	12.02%	40.13%	12.37%

Summary

Eton Pharmaceuticals beats ARS Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to GH Research?

GH Research (NASDAQ:GHRS) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

GH Research has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

56.9% of GH Research shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 41.6% of GH Research shares are held by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

GH Research has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -184.24%. GH Research's return on equity of -20.86% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.86%	-20.12%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

In the previous week, ARS Pharmaceuticals had 2 more articles in the media than GH Research. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 4 mentions for GH Research. GH Research's average media sentiment score of 0.45 beat ARS Pharmaceuticals' score of 0.16 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GH Research presently has a consensus price target of $45.00, suggesting a potential upside of 113.17%. ARS Pharmaceuticals has a consensus price target of $25.00, suggesting a potential upside of 491.02%. Given ARS Pharmaceuticals' higher probable upside, analysts plainly believe ARS Pharmaceuticals is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

GH Research has higher earnings, but lower revenue than ARS Pharmaceuticals. GH Research is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
ARS Pharmaceuticals	$116.93M	3.60	-$171.30M	-$2.18	N/A

Summary

GH Research beats ARS Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Rapport Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Rapport Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Rapport Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -184.24%. Rapport Therapeutics' return on equity of -29.02% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-29.02%	-27.37%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

In the previous week, Rapport Therapeutics had 5 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 11 mentions for Rapport Therapeutics and 6 mentions for ARS Pharmaceuticals. Rapport Therapeutics' average media sentiment score of 0.54 beat ARS Pharmaceuticals' score of 0.16 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rapport Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. Rapport Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A
ARS Pharmaceuticals	$116.93M	3.60	-$171.30M	-$2.18	N/A

68.2% of ARS Pharmaceuticals shares are held by institutional investors. 12.5% of Rapport Therapeutics shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rapport Therapeutics currently has a consensus target price of $66.11, suggesting a potential upside of 115.70%. ARS Pharmaceuticals has a consensus target price of $25.00, suggesting a potential upside of 491.02%. Given ARS Pharmaceuticals' higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Rapport Therapeutics beats ARS Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Ocular Therapeutix has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.Comparatively, ARS Pharmaceuticals has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

ARS Pharmaceuticals has a net margin of -184.24% compared to Ocular Therapeutix's net margin of -579.10%. Ocular Therapeutix's return on equity of -59.89% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-579.10%	-59.89%	-45.99%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

In the previous week, Ocular Therapeutix had 6 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 12 mentions for Ocular Therapeutix and 6 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.16 beat Ocular Therapeutix's score of 0.11 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ARS Pharmaceuticals has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	31.88	-$265.94M	-$1.42	N/A
ARS Pharmaceuticals	$116.93M	3.60	-$171.30M	-$2.18	N/A

Ocular Therapeutix currently has a consensus target price of $24.33, suggesting a potential upside of 222.72%. ARS Pharmaceuticals has a consensus target price of $25.00, suggesting a potential upside of 491.02%. Given ARS Pharmaceuticals' higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Ocular Therapeutix and ARS Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Phibro Animal Health?

Phibro Animal Health (NASDAQ:PAHC) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Phibro Animal Health has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52B	1.02	$99.72M	$2.44	15.70
ARS Pharmaceuticals	$116.93M	3.60	-$171.30M	-$2.18	N/A

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 48.5% of Phibro Animal Health shares are owned by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Phibro Animal Health has a net margin of 6.57% compared to ARS Pharmaceuticals' net margin of -184.24%. Phibro Animal Health's return on equity of 37.86% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

Phibro Animal Health presently has a consensus price target of $47.67, suggesting a potential upside of 24.46%. ARS Pharmaceuticals has a consensus price target of $25.00, suggesting a potential upside of 491.02%. Given ARS Pharmaceuticals' higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, ARS Pharmaceuticals had 3 more articles in the media than Phibro Animal Health. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 3 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.50 beat ARS Pharmaceuticals' score of 0.16 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phibro Animal Health has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Summary

Phibro Animal Health beats ARS Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

Get ARS Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRY vs. The Competition

Export

Metric	ARS Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$453.48M	$12.35B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-1.94	797.58	274.15	26.16
Price / Sales	3.60	757.87	589.97	94.50
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	3.65	10.71	11.21	6.34
Net Income	-$171.30M	$2.84B	$3.50B	$381.90M
7 Day Performance	3.93%	-0.93%	-0.90%	-1.41%
1 Month Performance	-16.40%	-4.91%	-4.44%	-3.48%
1 Year Performance	-62.63%	-4.13%	6.96%	1.16%

ARS Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRY ARS Pharmaceuticals	2.3012 of 5 stars	$4.23 -7.2%	$25.00 +491.0%	-63.5%	$453.48M	$116.93M	N/A	200
ETON Eton Pharmaceuticals	4.2601 of 5 stars	$55.62 +0.5%	$67.50 +21.4%	+172.2%	$1.58B	$105.60M	146.37	44	Insider Trade
GHRS GH Research	3.5381 of 5 stars	$22.17 -3.4%	$45.00 +103.0%	+60.2%	$1.57B	N/A	N/A	73	News Coverage
RAPP Rapport Therapeutics	2.74 of 5 stars	$32.19 +0.1%	$66.11 +105.4%	+14.6%	$1.54B	N/A	N/A	84	News Coverage Analyst Forecast Insider Trade
OCUL Ocular Therapeutix	3.479 of 5 stars	$7.25 +4.2%	$24.33 +235.6%	-36.9%	$1.53B	$52.06M	N/A	325

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRY) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ARS Pharmaceuticals (SPRY) Competitors

SPRY vs. ETON, GHRS, RAPP, OCUL, and PAHC

How does ARS Pharmaceuticals compare to Eton Pharmaceuticals?

Summary

How does ARS Pharmaceuticals compare to GH Research?

Summary

How does ARS Pharmaceuticals compare to Rapport Therapeutics?

Summary

How does ARS Pharmaceuticals compare to Ocular Therapeutix?

Summary

How does ARS Pharmaceuticals compare to Phibro Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY vs. The Competition

ARS Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ARS Pharmaceuticals (SPRY) Competitors

SPRY vs. ETON, GHRS, RAPP, OCUL, and PAHC

How does ARS Pharmaceuticals compare to Eton Pharmaceuticals?

Does the media favor SPRY or ETON?

Which has more risk & volatility, SPRY or ETON?

Which has stronger valuation & earnings, SPRY or ETON?

Do insiders & institutionals hold more shares of SPRY or ETON?

Do analysts rate SPRY or ETON?

Is SPRY or ETON more profitable?

Summary

How does ARS Pharmaceuticals compare to GH Research?

Which has more risk and volatility, GHRS or SPRY?

Do insiders and institutionals have more ownership in GHRS or SPRY?

Is GHRS or SPRY more profitable?

Does the media prefer GHRS or SPRY?

Do analysts rate GHRS or SPRY?

Which has stronger earnings and valuation, GHRS or SPRY?

Summary

How does ARS Pharmaceuticals compare to Rapport Therapeutics?

Which has more volatility and risk, RAPP or SPRY?

Is RAPP or SPRY more profitable?

Does the media prefer RAPP or SPRY?

Which has better valuation and earnings, RAPP or SPRY?

Do institutionals & insiders have more ownership in RAPP or SPRY?

Do analysts rate RAPP or SPRY?

Summary

How does ARS Pharmaceuticals compare to Ocular Therapeutix?

Which has more volatility and risk, OCUL or SPRY?

Is OCUL or SPRY more profitable?

Does the media refer more to OCUL or SPRY?

Do institutionals and insiders have more ownership in OCUL or SPRY?

Which has better earnings and valuation, OCUL or SPRY?

Do analysts prefer OCUL or SPRY?

Summary

How does ARS Pharmaceuticals compare to Phibro Animal Health?

Which has higher valuation and earnings, PAHC or SPRY?

Do institutionals & insiders have more ownership in PAHC or SPRY?

Is PAHC or SPRY more profitable?

Do analysts prefer PAHC or SPRY?

Does the media prefer PAHC or SPRY?

Which has more risk & volatility, PAHC or SPRY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY vs. The Competition

ARS Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools